Comparison of Efficacy and Safety of Infliximab and Ustekinumab in First-line Biological Therapy for Moderate-to-severe Inflammatory Bowel Disease:An Indirect Meta-analysis
10.3969/j.issn.1008-7125.2024.01.005
- VernacularTitle:英夫利西单抗和乌司奴单抗在中重度炎症性肠病一线生物治疗中疗效和安全性的比较:间接meta分析
- Author:
Yujia GAN
1
;
Linyan ZHOU
Author Information
1. 中国医科大学附属盛京医院消化内科(110004)
- Keywords:
First-Line Biological Therapy;
Infliximab;
Ustekinumab;
Crohn Disease;
Colitis,Ulcerative;
Indirect Meta-Analysis
- From:
Chinese Journal of Gastroenterology
2024;29(1):20-28
- CountryChina
- Language:Chinese
-
Abstract:
Background:With the increasing diversity of biological agents,the first-line biological agents for moderate-to-severe Crohn's disease(CD)and ulcerative colitis(UC)requires more precise positioning.Aims:To systematically evaluate the efficacy and safety of infliximab(IFX)and ustekinumab(UST)as first-line options for moderate-to-severe CD and UC.Methods:Randomized controlled trials(RCTs)on IFX and UST in treatment of moderate-to-severe CD and UC were retrieved from CNKI,Wanfang data,VIP,Chinese Science Citation Database and PubMed,Web of Science,Embase,ClinicalTrials,Cochrane Library from the date of database establishment to December 2023.An indirect meta-analysis was conducted to compare the efficacy and safety of IFX and UST in treatment of moderate-to-severe CD and UC.Results:Eleven RCTs were enrolled.No significant differences in clinical remission and maintenance rates of moderate-to-severe CD were found between IFX group and UST group(P>0.05),and no significant differences in serious adverse events and serious infection rates were found between these two groups(P>0.05).No significant differences in clinical remission and maintenance rates of moderate-to-severe UC were found between IFX group and UST group(P>0.05),and no significant differences in serious adverse events and serious infection rates were found between these two groups(P>0.05).Conclusions:Both IFX and UST can be served as first-line biological therapy for patients with moderate-to-severe CD.In view of the fact that IFX can increase the risk of tuberculosis,UST is recommended as first-line therapy for moderate-to-severe CD.For moderate-to-severe UC,IFX is an effective and safe first-line biological therapy,and UST can be served as an alternative.
